| Saturday, October 29. 2022 |
| Start |
End |
Function/Event |
Chair/Speakers |
Room |
| 7:00 AM |
8:00 AM |
Registration & Breakfast -Workshop Attendees |
|
Cottonwood 7 |
| 7:00 AM |
8:00 AM |
Breakfast - ISoP Board |
|
Spruce 3 |
| 8:00 AM |
5:30 PM |
ISoP Board Meeting |
|
Spruce 4 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop -Pumas for non-linear mixed effects modeling |
Pumas AI, Inc |
Cottonwood 3 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Introduction to Finch Studio for NONMEM Analyses with Case Studies in Target-Mediated Drug Disposition |
Enhanced Pharmacodynamics |
Cottonwood 4 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Introductory Course on Pharmacometric Modeling with Monolix |
Simulation Plus |
Cottonwood 5 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Advanced Features of NONMEM 7.5 Workshop for ACoP 2022 |
ICON |
Cottonwood 6 |
| 12:00 PM |
1:00 PM |
Lunch - Workshop Attendees |
|
Cottonwood 7 |
| 12:00 PM |
1:00 PM |
Board Lunch |
|
Spruce 3 |
| Sunday, October 30. 2022 - ACoP13 Conference |
| Start |
End |
Function/Event |
Chair/Speakers |
Room |
| 8:00 AM |
5:00 PM |
Speaker Ready Room |
|
Cottonwood 1 |
| 7:00 AM |
8:00 AM |
Registration & Breakfast - Workshop Attendees |
|
Cottonwood 7 |
| 7:15 AM |
8:30 AM |
Registration & Breakfast - Pre Con Attendees |
|
Cottonwood 8/9 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Pumas for non-linear mixed effects modeling (Day 2 of 2) |
Pumas AI, Inc |
Cottonwood 3 |
| 12:00 PM |
5:00 PM |
Pre Meeting Workshop - A showcase of open-source tools for scalable, reproducible PMx workflows |
Metrum |
Cottonwood 4 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Forest plots in practical use: Implementation and interpretation |
Pharmetheus |
Cottonwood 5 |
| 8:00 AM |
5:00 PM |
Pre Meeting Workshop - Advanced course on Pharmacometrics modeling with Monolix |
Lixoft, Simulation Plus |
Cottonwood 6 |
| 8:15 AM |
4:30 PM |
Pre Conference Session - "Challenging the Norm: IV/SC Bridging Strategies for Biologics" |
|
Maple 3 - 5 |
| 8:15 AM |
8:30 AM |
Welcome, Introduction & Problem Statement |
Sihem Bihorel-Merck & Co, Daniele Ouellet-Janssen (Pre-Conference Chairs) |
|
| 8:30 AM |
9:00 AM |
Clinical Considerations for mAbs PK Modeling and Simulations |
Sihem Bihorel-Merck & Co |
|
| 9:00 AM |
9:30 AM |
General PK Characteristics for mAbs & Modeling Considerations for mAbs SC Absorption - Preclinical |
Leonid Kagan-Rutgers University |
|
| 9:30 AM |
10:15 AM |
Bridging Strategy for mAbs - Introduction and Considerations for SC Development |
Jin Y. Jin-Genentech |
|
| 10:15 AM |
10:30 AM |
Break |
|
|
| 10:30 AM |
11:15 AM |
Successful Use of MIDD in Posology Bridging |
Jun Shen - BMS |
|
| 11:15 AM |
11:30 AM |
Selected Poster’s Abstract: Blinatumomab Trimer Formation - Insights from A Mechanistic PKPD Model On The Implications For Switching From Infusion To Subcutaneous Dosing Regimen In Acute Lymphoblastic Leukemia |
Georgi I. Kapitanov - Applied BioMath |
|
| 11:30 AM |
11:45 AM |
Selected Poster’s Abstract: PBPK modelling relates subcutaneous bioavailability of mAbs to the saturation of FcRn-mediated recycling in dosing site draining lymph nodes |
Felix Stader-Certara UK Ltd |
|
| 11:45 AM |
12:45 PM |
Lunch & Posters - Pre-Conference Attendees |
|
Cottonwood 8/9 |
| 12:45 PM |
1:15 PM |
Scientific Considerations for Biologics IV/SC Bridging Strategies - An FDA Experience |
Yow-Ming Wang - FDA |
|
| 1:15 PM |
2:15 PM |
Panel Discussion on Regulatory Considerations for Global Development |
Shinichi Kijima - PMDA,
Flora Musuamba - EMA,
Yow-Ming Wang - FDA,
Hao Zhu - FDA,
AMit Roy - BMS,
Lucia Zhang (Health Canada),
Jin Y. Jin-Genentech,
Daniele Ouellet - Janssen
Lucia Zhange - Health Canada
|
|
| 2:15 PM |
2:45 PM |
Coffee Break |
|
Maple Foyer |
| 2:45 PM |
3:45 PM |
How to Design an IV/SC Bridging Study With the Help of MIDD An Interactive Case Study Session |
Moderations: Marc Gastonguay - Metrum,
Anne-Gaelle Dosne - JanssenParticipants: All Attendees |
|
| 3:45 PM |
4:15 PM |
General Discussion from Case Study Session (Q&A). |
Panelists (Regulatory Agencies & Industry) |
|
| 4:15 PM |
4:30 PM |
Concluding Remarks, Wrap Up, and Adjourn |
Sihem Bihorel - Merck & Co, Daniele Ouellet - Janssen (Pre-Conference Chairs) |
|
| 12:00 PM |
1:00 PM |
Lunch - Workshop Attendees |
|
Cottonwood 7 |
| 2:15 PM |
2:45 PM |
Coffee Break - Workshop Attendees |
|
Cottonwood Foyer |
| 12:00 PM |
7:30 PM |
ACoP13 Conference Registration |
|
Adams Foyer |
| 5:00 PM |
5:30 PM |
ISoP Awards & Fellows Reception (by invitation only) |
|
Spruce 1 |
| 5:30 PM |
7:30PM |
ACoP13 Opening Session |
|
Adams B-D |
| |
|
Welcome/Conference Highlights |
Chris Penland, AstraZeneca (Conference Chair) |
|
| |
|
Presentation of ISoP Awards & Induction of Fellows |
Navin Goyal, Janssen (Awards Committee Chair) |
|
| |
|
Lewis B. Sheiner Award Lecture - “Lewis Sheiner’s Dream: A Long and Winding Road” |
Diane Mould - Projections Research Inc |
|
| 7:30 PM |
10:00 PM |
Opening Reception |
|
Adams Foyer |
| Monday, October 31, 2022 |
| Start |
End |
Function/Event |
Chair/Speakers |
Room |
| 8:00 AM |
5:00 PM |
Speaker Ready Room |
|
Cottonwood 1 |
| 7:00 AM |
9:00 AM |
Exhibits/Posters/Coffee Service |
|
Adams A |
| 9:00 AM |
11:00 AM |
General Session - President's Address/President-Elect's Address |
|
Adams B-D |
| |
|
ISoP: The Year in Review & Ahead |
CJ Musante - Pfizer (ISoP President) |
|
| |
|
State-of-the-Art Lecture - Advancing clinical trials in diabetes – opportunities and challenges
|
Dr. Hiddo J L Heerspink - University Medical Center Groningen |
|
| 11:15 AM |
1:00 PM |
Concurrent Session 1A - Oncology Drug Development - Getting Ready for Project Optimus |
Tim Nicholas - Pfizer & Wei Gao - EMD Serono |
Adams B-D |
| |
|
Project Optimus: Changing the Dosing Paradigm for Oncology Products |
Mirat Shah - FDA |
|
| |
|
Dose Optimization in Early Clinical Development for Oncology: Regulatory Perspective |
Jiang Liu - FDA |
|
| |
|
Leveraging Evolutionary Principles to Optimize Doses for Antibody-Targeted Therapy |
Carter Cao - UNC |
|
| |
|
Is QSP ready for Optimus? Opportunities and challenges with model informed oncology dose optimization. |
Blerta Shtylla - Pfizer |
|
| |
|
Integration of preclinical and early clinical data to inform rational oncology dose optimization strategy |
Donghua Yin - Pfizer |
|
| |
|
Dose Optimization in Oncology Drug Development: Opportunities and Enablers in the Context of Project Optimus |
Karthik Venkatakrishnan - EMD Serono |
|
| 11:15 AM |
1:00 PM |
Concurrent Session 1B - Opportunities and Challenges in Special Population Drug Development Applications of PBPK Modeling and Simulation for Small Molecules and Therapeutic Proteins |
Annie Lumen - AMgen, Blessy George - FDA, Xinwen Zhang - AMgen |
Maple 3-5 |
| |
|
Applications of MIDD for Pediatric Drug Development |
Gilbert Burckart - FDA |
|
| |
|
Model Informed Drug Development Application for Organ Impairment (Renal/Hepatic) Special Populations using PBPK Modeling & Simulation |
Vijay Upreti - AMgen |
|
| |
|
Use of Physiologically-Based Pharmacokinetic Modeling to Support Dosing in Pregnancy Considering Fetal Exposure |
Blessy George - FDA |
|
| |
|
PBPK Modeling and Simulation to Guide Pediatric Dosing for Therapeutic Proteins Through Various Routes of Administration |
Xinwen Zhang - AMgen |
|
| |
|
Mechanistic Predictive Modeling of Ocular Toxicity in Oncology Patients for Therapeutic Proteins using PBPK M&S |
Annie Lumen - AMgen |
|
| 11:15 AM |
1:00 PM |
Concurrent Session 1C - Modeling approaches to determine FIH dose for cell and gene therapeutics and novel modes of drug delivery in low data environments. |
Maithreye Rengaswamy - Vantage, Iraj Hosseini - Genentech |
Cottonwood 8/9 |
| |
|
Determining the Gene Expression Efficiency Factor for Model-based Development of the Viral-mediated in vivo Gene Therapy |
Chee Ng - NewGround LLC |
|
| |
|
Quantitative Translational and Clinical Pharmacology Approaches towards Effective Dose-selection for CAR-T Cell Therapies: Application towards MIDD |
Aman Singh - Takeda |
|
| |
|
IS/ID Modeling to Support the First in Human Dose Selection of an mRNA Cancer Vaccine |
Stephen Greene - Moderna Tx |
|
| |
|
Determining the FIH dose for an immune booster using a minimal PBPK-PD model |
Iraj Hosseini - Genentech |
|
| 1:00 PM |
2:30 PM |
Exhibits/Posters |
|
Adams A |
| 1:00 PM |
2:30 PM |
Lunch |
|
Adams Foyer |
| 1:00 PM |
2:30 PM |
Trainee Lunch |
Mokshada Kumar - SUNY Buffalo |
Cottonwood 6/7 |
| 1:00 PM |
2:30 PM |
JPKPD Meeting (invitation only) |
|
Maple 1 |
| 2:30 PM |
4:00 PM |
Concurrent Session 2A - Emerging Opportunities for Real World Evidence and Role of Pharmacometricians |
Arnab Mukherjee - Pfizer & Christopher Banfield - Pfizer |
Adams B-D |
| |
|
Regulatory perspectives on RWE guidance |
Hao Zhu - FDA |
|
| |
|
RWE study design and analytical considerations |
Lauren Becnel - Pfizer |
|
| |
|
Review of Case Studies of Clin Pharm/PMx applications of RWE at
Genentech |
Rui Zhu - Genentech |
|
| |
|
Panel Discussion |
Brian Corrigan - Pfizer, Vikram Sinha - Takeda, Ellen Wang - Pfizer, Rui Zhu - Genentech, Lauren Becnel - Pfizer |
|
| 2:30 PM |
4:00 PM |
Concurrent Session 2B - Modeling and Simulation in Support of New Modalities in Oncology Drug Development |
Hongmei Xu - Bicycle Therapeutics, Diansong Zhou - Astrazeneca |
|
| |
|
The application of PK/PD modelling in the clinical development of BT5528 - a novel toxin delivery platform |
Hongmei Xu - Bicycle Therapeutics |
|
| |
|
Challenges and opportunities of PKPD modeling of chimeric antigen receptor (CAR) T-cell therapy using ciltacabtagene autoleucel |
Yaming Su - Janssen |
|
| |
|
Mechanistic PK/PD Modeling in Support of Targeted Protein Degrader |
Vaishali Dixit - Kymeratx |
|
| |
|
MIDD on clinical development of T cell redirecting bispecific antibodies |
Xiling Jiang - FDA |
|
| 2:30 PM |
4:00 PM |
Concurrent Session 2C - The MPRINT Hub and BPCA: Moving Mountains in Maternal and Pediatric Precision Therapeutics |
Sara Quinney - Indiana University School of Medicine, Robert Bies - SUNY Buffalo |
Cottonwood 8/9 |
| |
|
The BPCA Framework Initiative and Enhancing Pediatric Drug Development and Therapeutics |
Gilbert Burckart - FDA |
|
| |
|
Utilizing pharmacometrics to support personalized therapy in pregnant and lactating women |
Sara Quinney - Indiana University School of Medicine |
|
| |
|
Towards Development of PBPK Models to Characterize the PK of Protein Therapeutics in Children |
Dhaval Shah - SUNY Buffalo |
|
| |
|
Daunorubicin PBPK model in Lean and Overweight Children |
Sanjana Parikh - Laboratory of Applied Pharmacokinetics and Bioinformatics, Saban Research Institute, CHLA |
|
| 4:00 PM |
5:30 PM |
Exhibits/Posters/Coffee Service |
|
Adams A |
| 5:30 PM |
7:00 PM |
Communication Challenge |
Stacey Tannenbaum - Astellas, Mirjam Trame - Certara, Mokshada Kumar -SUNY Buffalo |
Adams B-D |
| 7:00 PM |
10:00 PM |
Social Dinner Event |
|
Colorado Ballroom A |
| Tuesday, November 1, 2022 |
| Start |
End |
Function/Event |
Chair/Speakers |
Room |
| 8:00 AM |
5:00 PM |
Speaker Ready Room |
|
Cottonwood 1 |
| 7:30 AM |
9:30 AM |
Exhibits/Posters/Coffee Service |
|
Adams A |
| 9:30 AM |
10:45 AM |
General Session - Key Note Speaker - From mass (data) to energy (analytics) to power (decision-making), and how to shape the future of medical product development. |
Dr. Klaus Romero - Critical Path Institute |
Adams B-D |
| 11:00 AM |
12:30 PM |
Quality & Trainee Awards |
Lian Ma - FDA |
Adams B-D |
| |
|
Quality Award |
Gengbo Liu - Genentech, Logan Brooks - Genentech & John Canty - Genentech |
|
| |
|
Quality Award |
Rohit Rao - Pfizer |
|
| |
|
Quality Award |
Tara Yang - Parexel International |
|
| |
|
Trainee Award |
Aymara Sancho-Araiz - Universidad de Navarra (Inaki F. Troconiz accepting on behalf of Aymara) |
|
| |
|
Trainee Award |
Catherine Weathered - Purdue University |
|
| |
|
Trainee Award |
Thanh Bach - University of Iowa |
|
| 12:30 PM |
2:00 PM |
Exhibits/Posters |
|
Adams A |
| 12:30 PM |
2:00 PM |
Lunch |
|
Adams Foyer |
| 12:30 PM |
2:00 PM |
SIG Lunch - QSP (tickets required) |
|
Cottonwood 6 |
| 12:30 PM |
2:00 PM |
SIG Lunch - SxP (tickets required) |
|
Cottonwood 7 |
| 2:00 PM |
3:30 PM |
Concurrent Session 3A - Explainable Machine Learning for Disease Progression Modeling & Digital Twins |
James Lu - Genentech & Nicholas Ellinwood - Eli Lilly |
Adams B-D |
| |
|
Predicting disease activity in Multiple Sclerosis patients - an explainable ML approach in Mavenclad trials |
Nadia Terranova - Merck KGaA |
|
| |
|
An Explainable Deep Learning Framework for Tumor Dynamic Modeling and Overall Survival Prediction using Neural-ODE |
James Lu - Genentech |
|
| |
|
Neural ODEs for Multi-State Modeling and Cause-Specific Time-to-Event Analysis |
Stefan Groha - Dana-Farber Cancer Institute |
|
| |
|
Machine Learning Enables Smaller Clinical Trials |
Daniele Bertolini - Unlearn.ai |
|
| 2:00 PM |
3:30 PM |
Concurrent Session 3B - Advancing RNA-based therapeutics through model-informed development: current challenges and opportunities |
Vivaswath Ayyar - Janssen & Sukyung Woo - SUNY Buffalo |
Maple 3-5 |
| |
|
Mechanistic PK-PD modeling for siRNA Therapeutics |
Sukyung Woo - SUNY Buffalo |
|
| |
|
Translational Considerations for GalNAc-siRNA Development: Insights from a Minimal PBPK-PD Model |
Vivaswath Ayyar - Janssen |
|
| |
|
Pharmacometrics for Translational and Clinical Development of mRNA Vaccines and Therapeutics |
Min Liang - Moderna Tx |
|
| |
|
A translational quantitative systems pharmacology modeling framework for exon skipping oligonucleotide therapies for Duchenne muscular dystrophy |
Tomoki Yoneyama - Takeda |
|
| 2:00 PM |
3:30 PM |
Concurrent Session 3C - QSP modelers and conventional pharmacometricians meet at the nexus of late-stage clinical development: expanding the scope of MID3 |
Weirong Wang - Janssen & Vincent Lemaire - Genentech |
Cottonwood 8/9 |
| |
|
Quantitative systems pharmacology: Landscape analysis of regulatory submissions to the US Food and Drug Administration |
Justin Earp - FDA |
|
| |
|
What can pharmacometrics learn from QSP? |
Piet van der Graaf - Certara |
|
| |
|
What can QSP learn from pharmacometrics? |
Chuanpu Hu - Janssen |
|
| |
|
What can clinical development learn from QSP? |
Steven Chang - Immunetrics |
|
| 3:30 PM |
4:30 PM |
Exhibits/Posters/Coffee Service |
|
Adams A |
| 4:00 PM |
5:00 PM |
Trainee/Mentor Meeting |
Mokshada Kumar - SUNY Buffalo |
Cottonwood 6 |
| 5:00 PM |
6:00 PM |
Alumni Reception - U Of Tenn |
|
Maple 2 |
| 5:00 PM |
6:00 PM |
Alumni Reception - U of MD |
|
Spruce 1 |
| 5:00 PM |
6:00 PM |
Alumni Reception - U of Minn |
|
Spruce 2 |
| 5:00 PM |
6:00 PM |
Alumni Reception - U of Buffalo |
|
Spruce 3 |
| 5:00 PM |
6:00 PM |
Alumni Reception - U of FL |
|
Spruce 4 |
| 5:00 PM |
6:30 PM |
QSP SIG Reception |
Lourdes Cucurull-Sanchez - GSK |
Adams A |
| 6:00 PM |
7:30 PM |
President's Reception (by invitation only) |
|
Juniper B&C |
| Wednesday,November 2, 2022 |
| Start |
End |
Function/Event |
Chair/Speakers |
Room |
| 8:00 AM |
1:00 PM |
Speaker Ready Room |
|
Cottonwood 1 |
| 7:00 AM |
9:00 AM |
Exhibits/Posters/Coffee Service |
|
Adams A |
| 9:00 AM |
11:00 AM |
Roller Coaster 1 |
Pavan Vaddady - Daiichi Sankyo, Inc |
Maple 3-5 |
| |
|
From Casual to Causal: Three Fundamental Concepts to Spiff Up Your Causal Reasoning |
James Rogers - Metrum |
|
| |
|
Mathematical Modeling of ventilator-induced lung inflammation |
Sarah Minucci - Applied BioMath |
|
| |
|
Comparing the Applications of Machine Learning and PBPK/Pop-PK Models in Pharmacokinetic Drug-Drug Interaction Modelling |
Venkatesh Reddy - Astrazeneca |
|
| |
|
Regulatory Perspective on Artificial Intelligence Integrated Drug Development |
Ruihao Huang - FDA |
|
| |
|
PKPDAI: A Pharmacometric Knowledge Repository Structured and Curated with Natural Language Processing |
Frank Kloprogge - University College London |
|
| |
|
Disease Progression Modeling benefitting from emergence of novel approaches such as RWD & AI/ML |
Pascal Chanu - Genentech |
|
| 9:00 AM |
11:00 AM |
Roller Coaster 2 |
Wei Gao - EMD Serono |
Adams B-D |
| |
|
Quantitative clinical pharmacology considerations for cevostamab, an anti-FcRH5/CD3 TDB in relapsed or refractory multiple myeloma |
Monica Susilo - Genentech |
|
| |
|
Dose Justification Strategies for Teclistamab, an anti-BCMA/CD3 TDB in Relapsed or Refractory Multiple Myeloma |
Suzette Girgis - Janssen |
|
| |
|
Modeling Immunological Synapse Dynamics Induced by Bispecific T-cell Engagers |
Carter Cao - UNC |
|
| |
|
Evaluation of potential for subasumstat to overcome rituximab resistance via PK/PD and QSP modeling of antibody dependent cell mediated cytotoxicity |
Dean Bottino - Takeda |
|
| |
|
Quantitative Systems Pharmacology Modeling of Enzyme Replacement Therapies for Mucopolysaccharidosis Type II Reveals Key Brain & CSF PK/PD Relationships |
Mohammad Jafarnejad - Denali Therapeutics |
|
| |
|
Quantitative modeling to support Gene Therapy in Rare Diseases |
Satyaprakash Nayak - Pfizer |
|
| 9:00 AM |
11:00 AM |
Roller Coaster 3 |
Eric Sobie - Mount Sinai |
Cottonwood 8/9 |
| |
|
Generating Model-integrated Evidence for Developing and Approving Complex Generic LAI Products |
Liang Zhao - FDA |
|
| |
|
Rapid Decision Making: Utility of Automation and Pro-active modeling |
Jessica Wojciechowski - Pfizer |
|
| |
|
Association between Immune -mediated adverse events and treatment efficacy in patients treated with immune checkpoint inhibitors |
Agnish Dey - Takeda |
|
| |
|
Regulatory experience on the application of MIDD for COVID-19 EUA. |
Su-Young Choi - FDA |
|
| |
|
Establishing correlates of protection for herpes zoster infection via MBMA analysis. |
Maria-Luisa Sardu - Certara |
|
| |
|
Moving beyond boundaries: utilization of continuous bounded outcome score model in drug development decision making |
Yeamin Huh - Pfizer |
|
| 11:00 AM |
12:00 PM |
DE & I Session - Pharmacometric strategies to drive meaningful change in health equity |
Leticia Arrington - AMgen & Nadia Noormohamed - GSK |
Adams B-D |
| |
|
Introduction and ISoP DEI committee objectives |
Leticia Arrington - AMgen |
|
| |
|
Case Study: Attaining equity of access to research and evidence based medication use |
Catriona Waitt - University of Liverpool |
|
| |
|
Case Study: Expansion of the Cabotegravir Pre-exposure Prophylaxis (PreP) label to include transgender women by leveraging M&S approaches. |
Yash Gandhi - GSK |
|
| 12:00 PM |
1:30 PM |
Exhibits/Posters |
|
Adams A |
| 12:00 PM |
1:30 PM |
Lunch |
|
Adams Foyer |
| 12:00 PM |
1:30 PM |
SIG Lunch - CPmx (tickets required) |
|
Cottonwood 6 |
| 12:00 PM |
1:30 PM |
SIG Lunch - MCS (tickets required) |
|
Cottonwood 7 |
| 1:30 PM |
3:00 PM |
Concurrent Session 4A - PBPK and other extrapolation approaches in pediatrics: past, present and future |
Amy Cheung - Certara & James Yates - GSK |
Adams B-D |
| |
|
Regulatory landscape of PBPK, the progress of PBPK qualification and gaps for pediatric |
Ine Rusten - Systems Resource Lab (SRLAB), Flora Musuamba - EMA, FAMHP Belgium |
|
| |
|
Where are we with pediatric PBPK? |
Kunal Taskar - GSK |
|
| |
|
Model-based extrapolation to support new pediatric formulation approval without a single pediatric study? A case study with tofacitinib |
Cheng Chang - Pfizer |
new |
| 1:30 PM |
3:00 PM |
Concurrent Session 4B - Use of Bayesian joint modeling of longitudinal data and time to event data in drug development |
Wonkyung Byon - Amador Bio & Nidal Huniti - Amador Bio |
Maple 3-5 |
| |
|
An overview of joint modeling of longitudinal data and time to event data |
Luke Fostvedt - Pfizer |
|
| |
|
Use of joint modeling in oncology drug development: Challenges and
opportunities. |
Marion Kerioui - Memorial Sloan Kettering Cancer Center |
|
| |
|
Nasopharyngeal viral load reduction with early administration of anti–SARS-CoV-2 monoclonal antibodies was associated with decreased risk of disease progression in non-hospitalized patients with SARS-CoV-2 |
Daniela J Conrado - Regeneron & Yuhuan Wang - Regeneron |
|
| 1:30 PM |
5:00 PM |
Trainee Tutorial - Pharmacometric Analysis of Categorical data by Dr. Lena Friberg and Dr Andrew Hooker |
Mokshada Kumar - SUNY Buffalo, Lena Friberg - Uppsala University, Andrew Hooker - Uppsala University |
Cottonwood 8/9 |
| 3:15 PM |
3:45 PM |
Closing General Session |
|
Adams B-D |
| 4:30 PM |
6:00 PM |
ACoP 13 Meets ACoP 14 (by invitation only) |
|
Maple 1 |
| Thursday, November 3, 2022 |
| Start |
End |
Function/Event |
Speakers |
Room |
| 7:00 AM |
8:00 AM |
Tutorial Coffee Service |
|
Cottonwood Foyer |
| 8:00 AM |
12:00 PM |
Tutorial #1 - Stan and R for Stan-da-R-d Pharmacometric Analyses “ A Bayesian Approach for Population Pharmacokinetics and Exposure Response Modeling" |
Casey Davis - Gilead & Pavan Vaddady - Daiichi Sankyo [Instructors: Casey Davis - Gilead, Pavan Vaddady - Daiichi Sankyo, Arya Pourzanjani - AMgen, Yasong Lu - Daiichi Sankyo] |
Maple 3 - 5 |
| 8:00 AM |
12:00 PM |
Tutorial #2 - Using nlmixr2 for automatically selecting PK models with PKNCA |
Matthew Fidler - Novartis & William Denney - Human Predictions |
Cottonwood 8/9 |
| 12:00 PM |
1:00 PM |
Workshop Registration & Lunch (workshop attendee only) |
|
Spruce 3/4 |
| 1:00 PM |
5:00 PM |
Post Workshop - Bayesian Analysis in Pumas - (Almost) everything a Bayesian needs |
Pumas AI, Inc |
Spruce 1 |
| 1:00 PM |
5:00 PM |
Post Workshop - Exposure-response modeling for binary and time-to-event data using R and Stan |
Metrum |
Spruce 2 |
| 1:00 PM |
5:00 PM |
Post Workshop - Development of AI-based surrogates from Quantitative Systems Pharmacology models |
Mathworks |
|
| Friday, November 4, 2022 |
| Start |
End |
Function/Event |
Speakers |
Room |
| 7:00 AM |
8:00 AM |
Workshop Breakfast |
|
Spruce 3-4 |
| 8:00 AM |
5:00 PM |
Post Workshop - Bayesian Analysis in Pumas - (Almost) everything a Bayesian needs |
Pumas AI, Inc |
Spruce 1 |
| 8:00 AM |
5:00 PM |
Post Workshop - Exposure-response modeling for binary and time-to-event data using R and Stan |
Metrum |
Spruce 2 |
| 12:00 PM |
1:00 PM |
Workshop Lunch |
|
Spruce 3-4 |